The Foundation for Advancement in Cancer Research (FACR) is a non-profit organization supporting and researching effective non-toxic cancer modalities.

The Foundation for Advancement in Cancer Research (FACR) is a non-profit organization supporting and researching effective non-toxic cancer modalities. Poly-MVA[R] is a novel formula that contains a lipoic acid palladium composite (LAPd), its main active ingredient. The formula also contains riboflavin, cyanocobalamin, formyl-methionine, and acetylcysteine. The initials MVA stand for minerals, vitamins, and amino acids. Many studies and clinical experiences indicate that the LAPd originate in Poly-MVA may have a part to play in the treatment of a variety of cancers, including prostate cancer and lung cancer. lately we had the opportunity to discuss this formula's part in prostate and lung health with Dr Shari Lieberman, who, together with James W Forsythe MD HMD co-authored articles onward the subjects in Alternative and Complementary Therapies (August 2005; July 2006)

FACR: Prostate health is obviously of great affect to many men. How widespread is the incidence of prostate cancer?

Dr Lieberman: According to The Prostate Cancer Institute, prostate cancer is the single chiefly common form of solid tumor in humans. It's at hand in more than nine million men It afflicts common in six men in their lifetimes and is newly diagnosed each 2.6 minutes. Prostate cancer kills united man every 13 minutes. It strikes as many men (and causes almost as many deaths annually) as breast cancer does women still lacks the national awareness and research funding devot to breast cancer.

FACR: further prostate cancer is highly survivable if diagnosed early, correct?

Dr Lieberman: Ye and no. Conventional wisdom says that prostate cancer is nearly 100% survivable if find outed early. However, it is rarely find outed early because the technology to do in such a manner doesn't exist. Plus, it is generally asymptomatic. There's actually little evidence to confirm that early prostate cancer detection will converse 100% survival. This statistic can give a false sensation of security because it doesn't include the prognosis of hormone refractory prostate cancer, which is more difficult to treat and has a poorer prognosis. In addition, there is simply limited published data to remind of that early intervention of any image (androgen deprivation, radiation therapy, surgery etc) affects survival.

FACR: Prostate cancer is also true slow-growing, isn't it?

Dr Lieberman: That's correct--another reason on what account the 100% survivable statistic is misleading. Patients are more likely to die of other diseases before succumbing to the prostate cancer.

FACR: What are the standard forms of treatment for prostate cancer?

Dr Lieberman: Radical prostatectomy, cryotherapy, surgical castration, external bean radiation therapy, brachytherapy, luteinizing hormone-releasing hormone therapy, and combined androgen blockage have all been used. These treatments, however, are associated with numerous side meanings the most common being impotence. Radiation therapy also is associated with the progressive growth of secondary cancer. Consequently, many men single out the concept of "watchful waiting" to other standard treatments.

FACR: What can be done nutritionally to support conventional prostate cancer treatments?

Dr Lieberman: Poly-MVA is an prime choice both for those who make choice of the "watchful waiting" approach and those that want nutritional support as an adjuvant to standard treatment.

FACR: Poly-MVA is said to have a particularly interesting mechanism of action. Can you describe this?

Dr Lieberman: It actually has a two-step proces for its mechanisms of action. Poly-MVA is comprised of an irreversibly limit trimer of lipoic acid, a powerful water and fat-soluble antioxidant, and the mineral palladium with a thiamine (B1) core. Consequently it exists as a polymer rather than as a single atom That means Poly-MVA can accept and donate mechanical value (electron charge) at a earnestly greater magnitude then a single atom like other nutrients. This enables Poly-MVA to shuttle animal spirits to the mitochondria while, at the same time, protecting DNA and other cellular tissue from oxidative stres or clear radical damage that occurs during normal cellular metabolism and, especially, during times of disease (like cancer) or during the course of treatments (like radiation and chemotherapy). Essentially, Poly-MVA renews free radicals into usable cellular capacity of work benefiting and nourishing normal cells

FACR: Does this mean that Poly-MVA can provide the same pluck to cancer cells?

Dr Lieberman: No. Studies and long research have demonstrated that cancer solitary abode; squalids are unable to accept the exces strength Poly-MVA provides. This is because malignant solitary abode; squalids function in a hypoxic (low oxygen) environment, typically using sugar to generate the zeal needed to survive. The production of oxygen radicals from the bottom transfer generated in a hypoxic environment facilitates cancer small cavity death by activating enzymes that throw down the cells. Unlike cancer solitary abode; squalids healthy cells are richly oxygenated. Consequently Poly-MVA is non-toxic to the healthy small cavitys which benefit from the life boost and protective effect triggered through the Lipoic Acid Palladium complex